En Es
Categories

Industry News

Zoll Acquires Medical Device and Digital Health Company Itamar Medical

By HospiMedica International staff writers
14 Sep 2021

Image: WatchPAT device (Photo courtesy of Itamar Medical Ltd.)ZOLL Medical Corporation (Chelmsford, MA, USA), an Asahi Kasei company, has signed an agreement to acquire Itamar Medical Ltd. (Caesarea, Israel), a medical device and digital health company focused on the integration of sleep apnea diagnosis into the cardiac patient care pathway.

ZOLL manufactures medical devices and related software solutions, including multiple monitoring solutions that aid in the diagnosis and management of cardiac patients. Itamar Medical is focused on the development and commercialization of non-invasive medical devices and solutions to aid in the diagnosis of respiratory sleep disorders. The company has pioneered the WatchPAT Home Sleep Apnea Device, an innovative sleep apnea diagnosis program for patients and healthcare professionals. The WatchPAT device is FDA-cleared and continues to gain recognition as a safe and effective method for home-based testing for sleep apnea.

Research has shown complex interrelationships between cardiovascular disease and both obstructive sleep apnea (OSA) and central sleep apnea (CSA). OSA is associated with increases in the incidence and progression of coronary heart disease, heart failure, stroke, and atrial fibrillation, while CSA associated with Cheyne-Stokes respiration predicts incident heart failure and atrial fibrillation, and strongly predicts mortality among patients with heart failure.

“ZOLL Medical is committed to improving outcomes for underserved patients suffering from serious cardiopulmonary conditions,” said Jon Rennert, CEO of ZOLL Medical. “It is currently estimated that 60% of cardiovascular patients suffer from some form of sleep apnea, and the majority of these patients go undiagnosed. The combination of ZOLL Medical and Itamar Medical will help more patients receive diagnosis and treatment for sleep-disordered breathing. We look forward to helping strengthen the collaboration between the worlds of cardiology and sleep medicine.”

“We are excited to join forces with ZOLL Medical, a leader in addressing the needs of cardiologists and their patients. The integration of Itamar’s WatchPAT technology and Digital Health solution for sleep apnea with ZOLL Medical's commercial footprint will accelerate our mission of advancing home sleep medicine to benefit the population of undiagnosed and untreated patients,” said Gilad Glick, President and Chief Executive Officer of Itamar Medical.

Related Links:
ZOLL Medical Corporation
Itamar Medical Ltd.




E-mail Print
FaceBook Twitter Google+ Linked in

Additional news

22 Sep 2021
Thermo Fisher Launches World’s First Fully Integrated Digital PCR (dPCR) System
Thermo Fisher Scientific Inc. (Waltham, MA, USA) has launched the world’s first fully integrated digital PCR (dPCR) system designed to provide highly accurate and consistent results within 90 minutes.
Read More
17 Sep 2021
44th IHF World Hospital Congress Presents Over 60 Plenary Sessions and 200 Renowned Speakers Across Four-Day Event
The 44th World Hospital Congress organized by The International Hospital Federation (Geneva, Switzerland) will bring together more than 200 healthcare experts, leading industry thinkers, and best practice presenters at over 60 sessions around nursing leadership, humanizing technology, COVID-19 vaccination, the next global pandemic, etc.
Read More
17 Sep 2021
Global Digital Polymerase Chain Reaction (dPCR) Market Projected to Reach Close to USD 1.15 Billion by 2028
 The global digital polymerase chain reaction (dPCR) market is projected to grow at a CAGR of more than 9% from over USD 0.50 billion in 2020 to nearly USD 1.15 billion by 2028, driven primarily by rising infectious diseases, technological developments, as well as increased knowledge and acceptance of tailored treatments.
Read More
15 Sep 2021
Certest Offers Sensitive, Useful and Cheap CE-IVD Multiplex Assay for Rapid Diagnosis of Atypical Pneumonia
CerTest Biotec (Zaragoza, Spain) has developed and validated the CE-IVD multiplex assay VIASURE C. pneumoniae, M. pneumoniae & L. pneumophila real time PCR kit for the detection of principal pathogens implicated in atypical pneumoniae.
Read More
15 Sep 2021
Mesa Laboratories to Acquire Molecular Diagnostics Tools Company Agena Bioscience
Mesa Laboratories, Inc. (Lakewood, CO, USA) has entered into a definitive agreement to acquire Agena Bioscience, Inc. (San Diego, CA, USA).
Read More
13 Sep 2021
Global Blood, Gas and Electrolyte Analyzers Market Projected to Reach Nearly USD 3.50 Billion by 2023
The global blood, gas and electrolyte analyzers market is projected to grow at a CAGR of 8.6% from more than USD 2.10 billion in 2016 to nearly USD 3.50 billion by the end of 2023, driven by rapid developments in the healthcare sector that are resulting in the implementation of technologies to help care providers and patients in treating diseases. For instance, hospitals are implementing technologies like AR and VR that can provide real-time simulation of human body that can help them understand the anomaly of patients. However, the need for blood, gas analyzers to achieve greater accuracy and the requirement of regular maintenance are expected to hinder market growth.
Read More
09 Sep 2021
Stryker Completes Acquisition of Medical Device Company Gauss Surgical
Stryker (Kalamazoo, MI, USA) has completed the acquisition of Gauss Surgical (Menlo Park, CA, USA), a medical device company that has developed Triton, an artificial intelligence-enabled platform for real-time monitoring of blood loss during surgery.
Read More
08 Sep 2021
Global In Vitro Diagnostics (IVD) Quality Control Market Projected to Reach USD 1.4 Billion by 2026
The global in vitro diagnostics (IVD) quality control market is projected to grow at a CAGR of 5.3% from USD 1.1 billion in 2021 to USD 1.4 billion by 2026, thanks to the significant role played by IVD testing in clinical decision-making.
Read More
07 Sep 2021
Baxter to Acquire Hillrom, Targeting Expansion in Digital and Connected Care Solutions Worldwide
Two global medical technology giants have decided to join forces by way of Baxter's acquisition of Hillrom for approximately USD 10.5 billion in cash. Amounting to a total enterprise value of approximately USD 12.4 billion including assumption of debt, the transaction is expected to close in early 2022.
Read More
Copyright © 2000-2021 TradeMed.com. All rights reserved. | Terms And Conditions